ANI Pharmaceuticals, Inc.
http://www.anipharmaceuticals.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ANI Pharmaceuticals, Inc.
Finance Watch: Actuate Launches 15th Biopharma IPO In The US For 2024
Public Company Edition: Actuate Therapeutics grossed $22.4m in its first-time offering, while already-public companies recently tapped a variety of sources for funding. Arrowhead negotiated a credit facility for up to $500m and ANI sold $275m worth of notes, among other financings.
Asia Deal Watch: Ocumension Obtains Chinese Rights To Eight Alcon Products
Also deals involving WuXi/Medigene, Eisai/Seed, Genor/Two River/Third Rock Ventures, ImmuneOnco/Instil, Biocytogen/Ideaya, Takeda/Dr Reddy’s/Zydus/Mankind and deals in brief.
Northeast’s DCTY Deal Marks China’s First Domestic Biotech Acquisition Of '24
If closed successfully, the traditional producer of active pharmaceutical ingredients and generic drugs will scoop up the world’s second advanced KRAS G12D-targeting T-cell receptor (TCR) T cell therapy candidate, as well as an EGFR variant III-targeting chimeric antigen (CAR) receptor T-cell agent. Out-licensing efforts are already under way.
Boehringer Looks To Revitalise Its Pipeline
With sales of its big sellers Jardiance and Ofev to start shrinking in the next few years, the German group is teeing up a suite of new drugs.
Company Information
- Industry
- Contract Research Organization-CRO
- Services
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- BioSante Pharmaceuticals, Inc.
- Cell Genesys, Inc.
- Novitium Pharma LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice